August 6th 2025
Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
NCCN Report on CAR T-Cell Therapy, Recommendations for Future Use
Prescription Drug Coverage Improved Survival for Patients With MM
HIV/AIDS Research Has Positive Impacts Across Other Medical Fields
Bringing Virtual Tumor Boards, Real-Time Data to the Point of Care